Safety and efficacy of direct oral anticoagulation in patients with and without radiofrequency ablation of non-valvular atrial fibrillation: a multicenter retrospective cohort study.

"Declarations Ethics approval and consent to participateThe study complies with the Declaration of Helsinki and was authorized by The Ethics Committee of Fujian Medical University Union Hospital. Consent for publicationThe requirement for patient consent was waived due to its retrospective nature. Competing interestsThe authors declare no competing interests. Competing interests The authors declare no competing interests."

"Funding No specific funding was necessary for the conduct of this study."

"From January 2016 to December 2020, we conducted a multicenter retrospective registration at 15 centers in China (Supplementary Table ). Supplementary Fig. shows the distribution map of multicenter hospitals. The study registration number is ChiCTR2000031909. The inclusion criteria for this study were as follows: (1) age ≥18 years old; (2) diagnosis of NVAF; (3) treatment with DOACs; (4) patients with known ablation status and follow-up data during hospitalization at baseline. Exclusion criteria were: (1) patients with valvular AF; (2) taking warfarin or aspirin after discharge from the hospital. (3) Patients with incomplete basic data such as age and sex. Since apixaban has no indication for NVAF in China and edoxaban will only be available in China in 2019, the DOACs used in multicenter hospitals are rivaroxaban and dabigatran. A total of 6137 patients with NVAF treated with DOACs were eligible for this study after meeting the inclusion criteria. Of these, 2661 patients underwent radiofrequency ablation (RFA) during hospitalization, and 3476 did not undergo RFA."